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INTRODUCTION
Vagus nerve stimulation (VNS), repeated stimulation of
the left vagus nerve through implanted electrodes, is an em-
pirically based treatment method for epilepsy. Although VNS
induces changes in brain electrophysiology, metabolism and
neurochemistry in animals and humans, its mechanism of
action remains unknown. VNS has been used in epilepsy
patients who are refractory to standard medical treatments
and unsuitable candidates for resective or disconnective sur-
gery. Due to the possible unfavorable effects of multiple anti-
epileptic drugs on development, VNS is of particular inter-
est in children and adolescents; over 25% of the approxima-
tely 30,000 patients receiving vagus nerve stimulator im-
plants to date have been children and adolescents younger
than 18 yr of age (1). Moreover, VNS has shown a higher
degree of efficacy and tolerance in children than in adults (2).
Here we report our experience in this relatively new tech-
nique, including its long-term efficacy by seizure type, eti-
ology, and seizure duration, as well as its safety, in pediatric
patients with intractable epilepsy.
MATERIALS AND METHODS
The subjects consisted of 28 pediatric patients with intrac-
table epilepsy, defined as uncontrolled seizures on two or more
anti-epileptic drugs, in whom vagus nerve stimulators had
been implanted at the Epilepsy Centers of Sanggye Paik Hos-
pital, Asan Medical Center, and Severance Hospital in Korea,
from July 1999 to March 2005. All 28 patients had multi-
focal or generalized epilepsy, and were therefore not eligible
for epileptic surgery. Patients had various seizure etiologies,
seizure types, and/or epilepsy syndromes. All subjects were
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Vagus Nerve Stimulation in Intractable Childhood Epilepsy: a Korean
Multicenter Experience
We evaluated the long-term outcome of vagus nerve stimulation (VNS) in 28 children
with refractory epilepsy. Of these 28 children, 15 (53.6%) showed a >50% reduc-
tion in seizure frequency and 9 (32.1%) had a >75% reduction. When we compared
seizure reduction rates according to seizure types (generalized vs. partial) and eti-
ologies (symptomatic vs. cryptogenic), we found no significant differences. In addi-
tion, there was no correlation between the length of the stimulation period and treat-
ment effect. The seizure reduction rate, however, tended to be inversely related to the
seizure duration before VNS implantation and age at the time of VNS therapy. VNS
also improved quality of life in this group of patients, including improved memory in
9 (32.1%), improved mood in 12 (42.9%), improved behavior in 11 (39.3%), improved
altertness in 12 (42.9%), improved achievement in 6 (21.4%), and improved verbal
skills in 8 (28.6%). Adverse events included hoarseness in 7 patients, dyspnea at
sleep in 2 patients, and wound infection in 1 patient, but all were transient and suc-
cessfully managed by careful follow-up and adjustment of parameters. These results
indicate that VNS is a safe and effective alternative therapy for pediatric refractory
epilepsy, without significant adverse events.
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followed up for at least 12 months, and, in 26 of 28 patients,
their regimen of antiepileptic drugs was not changed during
the first 6 months.
The device used for VNS stimulation was purchased from
Cyberonics (Houston, TX). Each stimulation was for 30 sec,
initially at 0.25 mA output current, 30 Hz frequency, and
500  s pulse width, with 5 min between stimulations; para-
meters for each patient were adjusted in accordance with the
manufacturer’s guidelines (Fig. 1). We prospectively record-
ed seizure frequency and severity at 3, 6, and 12 months after
implantation, and at last follow-up (up to 6 yr), as well as all
adverse events. Quality of life parameters were measured using
the Korean version of the Quality of Life in Childhood Epilep-
sy questionnaire (K-QOLCE) (3).
SPSS version 13.0 was used for all statistical analyses. Dif-
ferences in dependent, categorical and continuous variables
were evaluated using two-tailed chi-square and Student’s t-
tests, and multiple regression analysis was used to evaluate
independent variables. A p-value<0.05 was regarded as sta-
tistically significant.
RESULTS 
Of the 28 patients, 16 were boys and 12 were girls; their
mean (±SD) age at the initiation of VNS was 9 yr 4 months
(±3 yr 10.2 months) (range, 2 yr 5 months to 17 yr 10
months). Of these 28 patients, 14 had Lennox-Gastaut syn-
drome (LGS), 2 had generalized seizures, one had severe myo-
clonic epilepsy in infancy, and 11 had partial seizures, includ-
ing one patient with gelastic seizures originating from a hy-
pothalamic hamartoma. Their mean (±SD) seizure duration
before VNS implantation was 6 yr, 11 months (±4 yr, 0.3
months) (range, 1 yr, 5 months to 17 yr, 10 months); and
the mean (±SD) follow-up after implantation was 31.4 (±
19.4) months (range, 12 months to 6 yr, 7 months). Their
detailed clinical profiles are summarized in Table 1.
VNS resulted in a >50% reduction in seizure frequency in
15 children (53.6%), with 9 (32.1%) achieving a >75% reduc-
tion in seizure frequency at last follow-up. We did not detect
any positive correlation between the length of the stimulation
period and the treatment effect. There were no significant
differences in the seizure type, etiology, mean age at starting
VNS therapy, or the mean seizure duration before VNS im-
plantation between children with a >50% and <50% reduc-
tion in seizure frequency (Table 2). We found, however, that
the seizure reduction rate tended to be inversely related to
seizure duration before VNS implantation and to the mean
age at the start of VNS therapy. 
A >50% reduction in seizure frequency was observed in 7
of the 11 patients (63.6%) with partial seizures and in 8 of
the 17 patients (47.1%) with generalized seizures. One patient
with complex partial seizures resulting from tuberous scle-
rosis complex showed a consistently favorable response, with
a >90% reduction in seizure frequency during VNS thera-
py. The one patient who had gelastic seizures from hypotha-
lamic hamartoma did not have a favorable response to VNS
therapy. 
Although the duty cycle was adjusted from 10% to 35%
in 5 patients who did not attain a satisfactory response, this
adjustment did not result in the anticipated reduction in sei-
zures, necessitating a return to the previous duty cycle. When
Fig. 1. Recommended protocol of VNS parameter settings.
VNS implantation
0.25 mA
After 2 weeks
if traumatic surgery
Immediately or
after 2-3 days
Every 1 week
over 4 weeks
Every 2 to 
4 weeks
Every 4 weeks
or
or
Every 4 weeks
3 months
after implantation
0.5-1.0 mA
1.0-1.5 mA
Adjusting duty cycle
until to 35%
every 3 mo.
Until to 3.5 mA
Returning to more
standard settings
SD, Standard deviation; HH, hypothalamic hamartoma.
Mean age (±SD) 9 yr 4 months (±46.2 months) 
Sex (Male/Female) 16/12
Mean seizure duration before  6 yr 11 months (±48.3 months)
implantation (±SD)
Mean follow-up duration (±SD) 31.4 months (±19.4 months)
Seizure type
Generalized seizures 17
Lennox-Gastaut syndrome 14
Unclassified generalized seizure 2
Severe Myoclonic Epilepsy in Infancy 1
Partial seizures 11
Secondary generalized tonic clonic seizure 10
Gelastic seizure with HH 1
Table 1. Demographics and clinical characteristics of the sub-
jects
VNS, Vagus nerve stimulation.
Seizure type p>0.05
Generalized seizure 8 9
Partial seizure 7 4
Etiology  p>0.05
Cryptogenic 8 9
Symptomatic 7 4
Mean age of starting VNS (yr) 9.1±3.6 9.5±4.3 p>0.05
Mean duration before VNS (months) 70.0±37.1 99.6±55.9 p>0.05
Seizure reduction rate
≥50% <50%
Table 2. Relationship of seizure reduction rate to clinical and
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these 5 patients were subjected to rapid cycling (longer on-
time and shorter off-time), 1 showed a >90% reduction in
seizure frequency. 
We compared quality of life (K-QOLCE) variables at base-
line and at follow-up, (minimum, 12 months). Of the 28
patients, 9 (32.1%) showed improved memory, 12 (42.9%)
each showed improved mood and alertness, 11 (39.3%) showed
improved behavior, 6 (21.4%) showed improved achievement,
and 8 (28.6%) showed improved verbal skills (Fig. 3).
Adverse events included hoarseness in 7 patients, dyspnea
at sleep in 2 patients, wound infection in 1 patient, and drool-
ing in 1 patient. All these adverse events were well tolerat-
ed or could be controlled by adjustment of output currents.
In one patient, wound revision was required. No adverse side-
effects such as bradycardia or arrhythmia were observed dur-
ing implantation and testing of the device inside the operat-
ing room.
DISCUSSION
In our evaluation of the long-term outcome and tolerabil-
ity of VNS in a group of Korean children with intractable
epilepsy, we found that VNS resulted in a >50% reduction
in seizure frequency in 53.6% of these children and a >75%
reduction in 32%. These results were similar to those of ear-
lier studies, in which 30% of patients had a >75% decrease
in seizure frequency 6 months after VNS implantation (1)
and 45% achieved a >50% reduction (2, 4-6). Although not
statistically significant, we found that this reduction in seizure
rate tended to be inversely related to seizure duration before
VNS implantation and to the mean age at starting VNS ther-
apy (2, 7). VNS also tended to be tolerated better and to be
more effective in younger patients. This may be due to the
degree of neuronal plasticity in the early years of life, before
long-standing epilepsy can cause permanent brain damage.
In agreement with previous findings, we also observed that
the efficacy of VNS therapy was not dependent on the
seizure type or seizure etiology (1, 8). One patient in our
series with tuberous sclerosis complex experienced a >90%
reduction in seizure frequency, in agreement with findings
that 5 of 10 patients with tuberous sclerosis complex expe-
rienced a >90% seizure reduction (9). Contrary to a previous
report (10), we found that our single patient with gelastic
seizure due to hypothalamic hamartoma did not respond
favorably to VNS therapy. Due to the limited number of pa-
tients in our study as well as their heterogeneous epileptic
syndromes and underlying etiologies, we could not stratify
our patients relative to the seizure type or etiology. Our find-
ings suggest, however, that VNS therapy is effective regard-
less of the seizure type or etiology. Although the effectiveness
of VNS has been reported to correlate positively with the
length of the treatment period (11, 12), we observed no cor-
relation between the duration of stimulation and treatment
effect. 
In addition to reducing seizures and seizure intensity, VNS
was associated with improvements in quality-of-life measure-
ments, including mood, alertness, verbal skills, memory, and
school/professional achievements, in many patients. In con-
trast to previous findings (11, 13-16), these effects were not
related to the anti-epileptic effects of VNS. For example, we
found that 2 of the 16 patients who experienced improve-
ments in quality of life measures showed no reduction in
seizure frequency. The nonpharmacologic aspects of VNS
therapy make it particularly attractive for use, particularly in
pediatric patients, due to the side effects and cognitive impair-
ments associated with anticonvulsants, accompanied in many
cases by mental retardation and delayed development (17).
The adverse events reported by VNS patients, including
voice alterations, coughing during stimulation, and drool-
ing, also occurred in our pediatric population (1). Several
patients reported increases in hyperactivity, a side effect uni-
que to this age group (14, 18). We also noted complications
such as hoarseness and dyspnea at sleep. Most of these side
effects, however, were transient or could be controlled by
adjusting the current output. However, most of these chil-
dren were mentally retarded and could not actively describe
their discomforts. 
In summary, our results indicate that VNS is a nonphar-
macologic option in treating children with intractable epi-
lepsy. It possesses several advantages, such as a lack of adverse
effects on cognitive functions, which are a major drawback
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Fig. 2. Changes in seizure reduction after 3, 6, and 12 months and
at last follow-up.
Fig. 3. Quality of life improvements.
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of antiepileptic drugs in pediatric patients undergoing criti-
cal stages of neural development. Our findings indicate that
VNS can be used as adjunctive treatment in children and
young adults with medically refractory seizures not amenable
to resective surgery.
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